跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT07216742
NCT07216742招募中3 期

A Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of a Human Menopausal Gonadotropin in the Development of Multiple Follicles, Pregnancy, and Cumulative Live Birth as Part of an Assisted Reproductive Technology (ART) Cycle.

Granata Bio Corporation16 个研究点 分布在 1 个国家目标入组 659 人开始时间: 2025年11月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
干预措施

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
659
试验地点
16
主要终点
cumulative live birth rate
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and cumulative live birth as part of an Assisted Reproductive Technology (ART) cycle in in women with a diagnosis of infertility.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 42 Years（Adult）
性别
Female
接受健康志愿者
否

入选标准

  • •Pre-menopausal women aged 18-42 years old at the time of consent.
  • •BMI ≥18 and <38 kg/m² at the time of consent.
  • •Menstrual cycles between 21-35 days.
  • •Normal mammogram or breast ultrasound if patient is >40 or if participant is younger as indicated by physician recommendation, within 2 years of screening.
  • •Anti-Müllerian hormone (AMH) >1.2 ng/ml within 6 months of screening.
  • •If donor sperm is used, donor must be 18-40 years of age at the time of collection and compliant with 21 Code of Regulations (CFR) section 1271 Subpart C.
  • •Transvaginal ultrasound (TVUS) documenting presence and adequate visualization of both ovaries without ovarian enlargement, normal adnexa, and both ovaries accessible for oocyte retrieval at screening or within 6 months of screening.
  • •Valid medical indication for in vitro fertilization (IVF) treatment and subsequent embryo transfer (i.e. history of infertility according to current American Society of Reproductive Medicine (ASRM) definition, single women or same-sex couples) with the intention to achieve pregnancy within 12 months of the first stimulation cycle.
  • •Hysterosalpingography, hysteroscopy or saline infusion sonography, documenting a normal uterine cavity (i.e. no müllerian duct anomaly, uterine fibroids, endometrial polyps, intrauterine adhesions, adenomyosis) at screening or within 1 year prior to screening.
  • •Normal cervical cytology/high risk human papillomavirus (HPV) testing per American College of Obstetrician/Obstetrician Gynecologist (OB/GYN) (ACOG) guidelines.
  • •Negative serum hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus (HIV) antibody tests at screening.
  • •Absence of hydrosalpinx confirmed by hysterosalpingogram (HSG), sonohysterogram, laparoscopy, or other appropriate imaging within the past 12 months.
  • •Willing to undergo up to two ovarian stimulation cycles prior to frozen embryo transfer.
  • •Willing to self-administer study medications.
  • •Willing to have trophectoderm biopsy of all blastocyst stage embryos.
  • •Willing to accept transfer of one euploid embryo.
  • •Willing to vitrify and warm embryo(s) with intention to have a Frozen Embryo Transfer (FET).
  • •Willing and able to comply with the protocol and schedule of events for the duration of the study as well as providing delivery data and neonatal health data.

排除标准

  • •Persistent ovarian cysts (≥11 mm) for >1 cycle or ovarian endometrioma on ultrasound (Principal Investigator's [PI] discretion).
  • •Participants with hepatic impairment (liver function tests > 2x upper limit of normal). Participants with renal impairment (estimated creatinine clearance <60 mL/min/1.73 m2).
  • •Uncontrolled adrenal or thyroid dysfunction.
  • •Greater than one IVF cycle canceled due to inability to meet ovulation trigger criteria (i.e. at least 2-3 follicles reach ≥18 mm.).
  • •History of recurrent implantation failure (RIF), defined according to the Lugano Consensus as the absence of implantation after transfer of ≥4 good-quality embryos in ≥3 embryo transfer (ET) cycles in women under the age of 40, using autologous oocytes.
  • •Recurrent pregnancy loss (RPL) is defined by two or more miscarriages; that is clinical pregnancies with the same partner and documented by ultrasonography or histopathological examination.
  • •Known history of anovulation.
  • •Antral Follicle Count (AFC) <5 at screening.
  • •One or more follicles ≥11 mm observed on TVUS prior to randomization on stimulation day
  • •Past or current history of an estrogen dependent malignancy
  • •Untreated atypical endometrial hyperplasia
  • •Any contraindication to the use of oral contraceptives
  • •History of OHSS.
  • •Morphological sperm evidence of globozoospermia or prior failed oocyte fertilization in previous IVF cycle.
  • •The use of donor sperm back up or rescue for fertilization of oocytes.
  • •Use of calcium ionophore or treatment of sperm with methyl xanthines.
  • •The need for surgically retrieved sperm (i.e. testicular sperm extraction [TESE], Percutaneous Epididymal Sperm Aspiration [PESA]).
  • •Use of any investigational drug throughout the study, or within 3 months before screening or 5 half-lives whichever is longer.
  • •Any concomitant medication that would interfere with the evaluation of the study medication (anti-psychotics, anxiolytics, hypnotics, sedatives, non-study hormonal therapy, except thyroid medication,).
  • •Current use or dependence on psychotropic medications that are contraindicated during pregnancy or have known or suspected fetal risk
  • •Required chronic use of non-steroidal anti-inflammatory drugs during cycle.
  • •Treatment with clomiphene citrate, metformin, gonadotropins, or GnRH analogs within 1 month prior to randomization.
  • •Pregnancy, lactation, or contraindication to gonadotropins.
  • •Known thrombophilia or history of blood clots unless fully evaluated and cleared by a hematologist and receiving appropriate prophylaxis.
  • •Known abnormal karyotype in the patient or her partner that is considered clinically significant, such as numerical or structural chromosomal abnormalities (e.g., translocations, inversions, aneuploidies) known to impair fertility, increase risk of miscarriage, or result in genetic disorders in offspring.
  • •Current tobacco user.
  • •Current or past (last 12 months) abuse of alcohol or drugs.
  • •Current use of dietary supplements containing high dose of biotin (>300µg), if prior use washout period of 1 week prior to randomization.
  • •No use of bioidentical hormones during stimulation or up to three months prior to start of stimulation. If prior use: washout period of three months prior to being randomized.
  • •A history of chemotherapy or radiotherapy.
  • •Undiagnosed uterine bleeding.
  • •Tumors of the ovary, breast, adrenal gland, pituitary, or hypothalamus; malformation of sexual organs incompatible with pregnancy.
  • •Known active pelvic inflammatory disease.
  • •Current, untreated submucosal fibroids or Intramural fibroids ≥5 cm or otherwise clinically relevant pathology that could impair embryo implantation or pregnancy continuation.
  • •The presence of severe endometriosis (ASRM stage 3 or stage 4) confirmed by laparoscopy, Magnetic Resonance Imaging (MRI), or pelvic ultrasound.
  • •Concomitant participation in another study protocol.
  • •Couples identified as carriers of the same autosomal recessive genetic condition associated with serious health outcomes in offspring will be excluded from the trial.
  • •Planned use of a gestational carrier.

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo, daily subcutaneous injection

干预措施: Placebo (Drug)

hMG

Experimental

Human Menopausal Gonadotropin, daily subcutaneous injection

干预措施: hMG subcutaneous injection (Drug)

结局指标

主要结局

cumulative live birth rate

时间窗: 12 months

cumulative live birth rate following vitrified-thawed, single-euploid blastocyst transfer(s)

次要结局

  • Positive pregnancy (serum β-human chorionic gonadotropin [hCG])(10 +/-2 days after Embryo transfer)
  • Ongoing pregnancy (intrauterine pregnancy with fetal heartbeat)(10 weeks ± 6 days post-embryo transfer (ET))
  • Fertilization rate (proportion of MII oocytes with normal fertilization)(12-22 days after Controlled Ovarian stimulation start)
  • FSH level on stimulation day 5(After 5 day of stimulation)
  • LH level on stimulation day 5(After 5 day of stimulation)
  • FSH level on last stimulation day(12-20 days after controlled ovarian stimulation start)
  • Clinical pregnancy (intrauterine gestational sac with fetal heartbeat)(5 weeks ± 6 days post-embryo transfer)
  • Live birth rate(9 months after ET)
  • Number of oocytes retrieved per stimulation cycle(12-22 days after controlled ovarian stimulation start)
  • Serum estradiol concentration on the day of ovulation trigger(12-20 days after controlled ovarian stimulation start)
  • Number of metaphase II (MII) oocytes retrieved(12-22 days after controlled ovarian stimulation start)
  • Number of Day 5 blastocysts from oocyte retrievals from Period 1 and Period 2(12-22 days after controlled ovarian stimulation start)
  • Total gonadotropin dose required per stimulation cycle(12-20 days after start Controlled ovarian stimulation)
  • Serum Luteinizing hormone (LH) level on stimulation day 1, pre-dose(1 day of stimulation)
  • Serum human Chorionic Gonadotropin (hCG) level on stimulation day 1, pre-dose(1 day of stimulation)
  • hCG level on stimulation day 1, 1-4 hours post dose(1 day of stimulation)
  • hCG level on stimulation day 5(After 5 day of stimulation)
  • Serum progesterone (P4) on Day 5 of stimulation(5 days after start controlled ovarian stimulation)
  • Serum Follicular Stimulation Hormone (FSH) level on stimulation day 1, pre-dose(1 day of stimulation)
  • FSH level on stimulation day 1, 1-4 hours post dose(1 day of stimulation)
  • LH level on stimulation day 1, 1-4 hours post dose(1 day of stimulation)
  • LH level on last stimulation day(12-20 days after controlled ovarian stimulation start)
  • hCG level on last stimulation day(12-20 days after controlled ovarian stimulation start)
  • FSH level on oocytes retrieval day(12-22 days after controlled ovarian stimulation start)
  • LH level on oocytes retrieval day(12-22 days after controlled ovarian stimulation start)
  • hCG level on oocytes retrieval day(12-22 days after controlled ovarian stimulation start)

研究者

发起方
Granata Bio Corporation
申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验

尚未招募
3 期
Effect of Finerenone in IgA NephropathyIgA Nephropathy
NCT06580288Zhejiang University120
Unknown
1 期
Clinical study to evaluate the safety, tolerability and pharmacokinetics of ZYDPLA1, a novel DPP- IV inhibitor, following oral administration in healthy volunteers.
CTRI/2016/04/006885Cadila Healthcare Limited112
已完成
1 期
Clinical study to evaluatethe safety, tolerability and pharmacokinetics of ZYAN1, a novel PHD-2 Inhibitor,following oral administration in healthy volunteers.
CTRI/2016/02/006665Cadila Healthcare Limited84
招募中
3 期
Probucol for Symptomatic Intracranial and Extracranial Artery StenosisIschemic StrokeTIA
NCT06225752First Affiliated Hospital of Wannan Medical College5,452
已完成
3 期
RCT for Pregabalin in Restless Legs Syndrome in South KoreaRestless Legs Syndrome
NCT04161027Seoul National University Hospital116